Iovance Biotherapeutics

Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapy for people with cancer. The company is pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognize and attack diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance is committed to continuous innovation in cell therapy, including gene-edited cell therapy, which may be a promising option for patients with cancer. Its product lineup includes Amtagvi and Proleukin, and the company operates the Iovance Cell Therapy Center for manufacturing.